Ovarian serous cystadenocarcinoma (OV) Samples Report
2014_12_06 Data Snapshot
- Overview
+ Introduction
- Summary

There were 48 redactions, 205 replicate aliquots, 0 blacklisted aliquots, and 0 FFPE aliquots. The table below represents the sample counts for those samples that were ingested into firehose after filtering out redactions, replicates, and blacklisted data, and segregating FFPEs.

Table 1.  This table provides a breakdown of sample counts on a per sample type and, if applicable, per subtype basis. Each count is a link to a table containing a list of the samples that comprise that count and details pertaining to each individual sample (e.g. platform, sequencing center, etc.). Please note, there are usually multiple protocols per data type, so there are typically many more rows than the count implies.

Sample Type BCR Clinical CN LowP Methylation mRNA mRNASeq miR miRSeq RPPA MAF
TP 601 589 583 0 592 572 295 568 453 412 316
TR 12 12 18 0 18 17 4 18 8 0 0
NB 454 452 441 0 0 0 0 0 0 0 0
NT 133 125 130 0 12 8 0 8 0 0 0
Totals 602 590 586 0 594 574 296 570 453 412 316

The sample type short letter codes in the table above are defined in the following list.

  • TP: Primary Solid Tumor

  • TR: Recurrent Solid Tumor

  • TB: Primary Blood Derived Cancer - Peripheral Blood

  • TAP: Additional - New Primary

  • TM: Metastatic

  • TAM: Additional Metastatic

  • NB: Blood Derived Normal

  • NT: Solid Tissue Normal

  • NBC: Buccal Cell Normal

  • NBM: Bone Marrow Normal

The following platforms are outdated and are not included in the counts depicted in the table above.

  • Agilent SurePrint G3 Human CGH Microarray Kit 1x1M

  • Agilent Human Genome CGH Microarray 244A

  • Agilent Human Genome CGH Custom Microarray 2x415K

  • Affymetrix Human Exon 1.0 ST Array

  • Illumina DNA Methylation OMA002 Cancer Panel I

  • Illumina DNA Methylation OMA003 Cancer Panel I

  • Illumina Human1M-Duo BeadChip

  • Illumina 550K Infinium HumanHap550 SNP Chip

Figure 1.  Get High-res Image This figure depicts the distribution of available data on a per participant basis.

- Results
+ FFPE Cases
+ Additional Annotations from the DCC's Annotations Manager
+ Methods & Data